title: Evaluation of Vitronectin Expression in Prostate Cancer and the Clinical Significance of the Association of Vitronectin Expression with Prostate Specific Antigen in Detecting Prostate Cancer.
abstract: OBJECTIVE
  To detect the expression of vitronectin (VTN) in the tissues and blood serum of prostate cancer (PCa) patients, and evaluate its clinical significance and to evaluate the significance of the combined assay of VTN and prostate specific antigens (PSA) in PCa diagnosis.
  
  
  METHODS
  To detect the expression of VTN as a potential marker for PCa diagnosis and prognosis, immunohistochemistry was performed on the tissues of 32 patients with metastatic PCa (PCaM), 34 patients with PCa without metastasis (PCa), and 41 patients with benign prostatic hyperplasia (BPH). The sera were then subjected to Western blot analysis. All cases were subsequently examined to determine the concentrations of PSA and VTN in the sera. The collected data were collated and analyzed.
  
  
  RESULTS
  The positive expression rates of VTN in the tissues of the BPH and PCa groups (including PCa and PCaM groups) were 75.61% and 45.45%, respectively (P = .005). VTN was more highly expressed in the sera of the BPH patients (0.83 &plusmn; 0.07) than in the sera of the PCa patients (0.65 &plusmn; 0.06) (P &lt; .05). It was also more highly expressed in the sera of the PCa patients than in the sera of the PCaM patients (0.35 &plusmn; 0.08) (P &lt; .05). In the diagnosis of BPH and PCa, the Youden indexes of PSA detection, VTN detection, and combined detection were 0.2620, 0.3468, and 0.5635; the kappa values were 0.338, 0.304, and 0.448, respectively, and the areas under the receiver operating characteristic curve were 0.625, 0.673, and 0.703 (P &lt; .05), respectively.
  
  
  CONCLUSIONS
  VTN levels in sera may be used as a potential marker of PCa for the diagnosis and assessment of disease progression and metastasis. The combined detection of VTN and PSA in sera can be clinically applied in PCa diagnosis.&nbsp.
authors.affiliation: Affiliated Tumor Hospital of Xinjiang Medical University, Xinjiang, China.
authors.forename: Yue
authors.initials: Y
authors.lastname: Niu
authors.affiliation: Center for Disease Control and Prevention of Xinjiang Uygur Autonomous Region, Xinjiang, China.
authors.forename: Ling
authors.initials: L
authors.lastname: Zhang
authors.affiliation: Affiliated Tumor Hospital of Xinjiang Medical University, Xinjiang, China.
authors.forename: Xing
authors.initials: X
authors.lastname: Bi
authors.affiliation: Affiliated Tumor Hospital of Xinjiang Medical University, Xinjiang, China.
authors.forename: Shuai
authors.initials: S
authors.lastname: Yuan
authors.affiliation: Affiliated Tumor Hospital of Xinjiang Medical University, Xinjiang, China. 414355314@qq.com.
authors.forename: Peng
authors.initials: P
authors.lastname: Chen
mesh_terms: D000368:Aged; D014408:Biomarkers, Tumor / Q000378:metabolism; D001706:Biopsy; D015153:Blotting, Western; D006801:Humans; D007150:Immunohistochemistry; D008297:Male; D011379:Prognosis; D011467:Prostate / Q000378:metabolism* / Q000473:pathology; D017430:Prostate-Specific Antigen / Q000378:metabolism*; D011471:Prostatic Neoplasms / Q000175:diagnosis / Q000378:metabolism*; D012372:ROC Curve; D019096:Vitronectin / Q000096:biosynthesis*
chemical_list: D014408:Biomarkers, Tumor; D019096:Vitronectin; D017430:Prostate-Specific Antigen